Table 2 The association between the tumor burden and clinical outcomes in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors.

From: Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors

 

N

Univariate analysis

Multivariate analysis

Progression-free survival

Overall survival

Progression-free survival

Overall survival

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

BNML

One

42

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

More

52

1.91

1.17–3.12

0.010

2.58

1.38–4.80

0.002

1.98

1.19–3.29

0.008

2.19

1.15–4.18

0.017

BSLD

 ≤ 28

33

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

 > 28

61

2.17

1.27–3.69

0.004

4.47

1.99–10.03

 < 0.001

2.57

1.44–4.58

0.001

3.10

1.30–7.41

0.011

SUVmax

 ≤ 12.93

23

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

 > 12.93

25

2.34

1.16–4.70

0.017

3.65

1.46–9.16

0.006

3.85

1.71–8.65

0.001

1.93

0.60–6.25

0.271

  1. Adjusted by age, sex, Eastern Cooperative Oncology Group performance status. In analysis for overall survival, adjusted also by best overall response for anti-PD-1 monotherapy.
  2. HR hazard ratio, CI confidence interval, BNML the baseline number of metastatic lesions, BSLD the baseline sum of the longest diameters of the target lesions, SUV standardized uptake value.
Back to article page